Matthew Geriak, Pharm.D. is an Investigational Research Pharmacist at an institution in San Diego, California, and an Adjunct Clinical Associate Professor at Touro University California. He has 22 years of experience in hospital pharmacy and 10 years’ experience as an Investigational Research Pharmacist. He received his Pharm.D. from the University Read more
Will the smaller clinical trial sites survive?
Increasing competition for a shallow, specialized patient pool is putting pressure on small standalone sites- which may be terminal. One solution may be the formation of site networks. hyperCORE International, a “super network” of clinical research site organizations, has just formed the second largest site network in the world, with more than 80 sites across five countries on two continents. (ACRP Net)
North America leads the clinical trials market
The global clinical trials market size is expected to reach USD 6.89 billion by 2026, and one of the key drivers is the globalization of clinical trials. North America leads the market in terms of revenue share; Phase III trials are expected to dominate the market; and the oncology segment will grow the fastest. (Yahoo Finance)
Cost of clinical trials doubles in a decade

Clinical trials have recently become very complex, especially for small and medium biotech companies, due to increased costs and regulatory requirements. Between 2008 and 2019, the cost of clinical trials increased by around 100 percent. In a 2018 study, a central cluster of trials had estimated costs of $12.2 million to $33.1 million. The trials cost a median of $41,117 per patient and $3,562 per patient visit. (Clinical Leader)
Training is a hot topic at ACRP
Improving clinical monitor and coordinator training was a hot topic at the recent ACRP 2019 conference. The clinical trial professional of the future will need the skills to deal with increasingly complex protocols and ever-evolving technologies. According to one speaker, “In 18 months, half of what we know now will be irrelevant.” (CenterWatch)
Pipelines and Patients

— by John Neal The clinical research industry continued its rapid evolution during 2018, coming off of a year of major activity and changes in 2017. It is no time for the faint of heart, or those resistant to change. As I first predicted in 2016 in my “Change is Read more
Clinical research industry’s 3 wishes for 2019
What might the clinical research industry wish for in 2019 to improve their ability to bring new products to market? Innovation in patient recruitment; blockchain to improve clinical research data storage; and a greater variety of eClinical platforms to meet the needs of researchers in different areas. (medrio)
Outgoing GSK exec shares four industry mega-trends
A number of global ‘mega-trends’, such as dated technology and manufacturing inefficiencies, present major challenges for the drug industry, according to Dave Tudor. (BioPharma-Reporter.com)